VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 107 filers reported holding VAXCYTE INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $378,335,377 | +7.2% | 7,421,251 | +5.0% | 0.01% | +10.0% |
| Q2 2023 | $352,830,495 | +85.2% | 7,065,088 | +39.0% | 0.01% | +66.7% |
| Q1 2023 | $190,468,300 | -22.2% | 5,081,865 | -0.5% | 0.01% | -25.0% |
| Q4 2022 | $244,802,492 | +192.1% | 5,105,370 | +46.2% | 0.01% | +166.7% |
| Q3 2022 | $83,817,000 | +17.7% | 3,492,321 | +6.7% | 0.00% | +50.0% |
| Q2 2022 | $71,188,000 | +2.1% | 3,271,630 | +13.4% | 0.00% | 0.0% |
| Q1 2022 | $69,698,000 | +5.5% | 2,886,022 | +3.9% | 0.00% | 0.0% |
| Q4 2021 | $66,066,000 | +3.1% | 2,777,047 | +10.0% | 0.00% | 0.0% |
| Q3 2021 | $64,051,000 | +21.3% | 2,524,645 | +7.6% | 0.00% | +100.0% |
| Q2 2021 | $52,821,000 | +22.2% | 2,346,617 | +7.2% | 0.00% | 0.0% |
| Q1 2021 | $43,228,000 | -3.9% | 2,188,728 | +29.3% | 0.00% | 0.0% |
| Q4 2020 | $44,983,000 | -9.3% | 1,693,028 | +68.5% | 0.00% | -50.0% |
| Q3 2020 | $49,603,000 | +1866.0% | 1,004,528 | +1158.6% | 0.00% | – |
| Q2 2020 | $2,523,000 | – | 79,812 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |